Tapimmune - TPIV

Tapimmune (TPIV)
Coverage: January 21, 2010 - March 21, 2010
Featured: January 21, 2010

Latest Newsletter Editions

Sat, May 22, 2010 @ 02:05 pm
There was a little relief rally on Friday after a fairly wicked week in the markets. Thursday's giant sell down felt like a "cash at any cost" down draft, with almost no regard for value. That's fine with me. These kinds of emotional, momentum driven markets present opportunities for those with the...
Tue, May 18, 2010 @ 10:05 am
A Busy Day- Comments on a Bunch of Stuff Frankly, it's a bit annoying. I wish these smaller companies could get their quarterly numbers out over a few week period in time, instead of all in one or two days at the absolute deadline. I just can't get quality commentary out fast enough for investors to...
Mon, Feb 1, 2010 @ 03:02 pm
Nothing Like a Cool $200 Million You might wonder who's got the cool $200 million, and what it has to do with today's edition of the OTC Journal. Remember my short term trading idea?- TapImmune (OTC BB: TPIV) I said some positive developments would start to roll their way, and today's post close news...
Wed, Jan 27, 2010 @ 09:01 am
Two Beat Downs; Stand By I just wanted to publish a couple of quick notes on two stocks I've been covering and have made comments on recently. First on China Recycling Energy (CREG)- someone is selling the stock fairly ruthlessly with little regard for price. It started two days ago, and the stock is...
Thu, Jan 21, 2010 @ 01:01 pm
How The Immune System Fights Disease Our bodies have a miraculous capability. Our Immune System, through a complex network of cells and chemicals, has the ability to identify bad stuff and rapidly recruit an army to attack foreign invaders and kill them. T-Cells are the circus ring masters. The T-Cells...


Latest Blog Entries


Quote Data

Last Trade: Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: Bid x Ask Size:
Change: +0.0000 (+0.00%) Day's Range: 0.00 - 0.00
Prev Close: 0.0000 52wk Range: 0.00 - 0.00
Open: 0.0000 P/E (ttm):
Volume: 0 EPS (ttm):
spacer [Chart]

Business Summary

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others.


MarketByte LLC has purchased 400,000 shares of Tapimmune with a cost basis of 7.5 cents from a non affiliate shareholder. The shares are freely tradeable. This should be construed as a form of compensation and a conflict of interest. The aforementioned shares could be sold at anytime without prior notification.

Recent News Headlines

TAPIMMUNE INC Files SEC form 10-K, Annual Report
Tue, 15 Apr 2014 21:18:43 GMT
TapImmune Inc. is Pleased to Provide an Update on Corporate Events and Milestones for 2014
Thu, 03 Apr 2014 15:03:00 GMT
[Business Wire] - TapImmune Inc. , A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update shareholders and investors on the most recent corporate events and milestones for the year ahead.
Thu, 27 Mar 2014 17:04:15 GMT
TapImmune Inc. is Pleased to Announce the Filin...[+]
Thu, 20 Mar 2014 13:42:57 GMT
[at noodls] - March 20, 2014, Seattle WA, TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious ...
TapImmune Inc. is pleased to announce the signi...[+]
Wed, 19 Mar 2014 13:57:45 GMT
[at noodls] - March 19, 2014, Seattle WA, TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious ...
TAPIMMUNE INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; C
Mon, 03 Mar 2014 17:23:48 GMT
TapImmune Releases Positive Interim Data on Pha...[+]
Mon, 03 Mar 2014 14:21:50 GMT
[at noodls] - March 3 2014, Seattle WA, TapImmune Inc. (OTCQB: TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients ...
TapImmune Chairman and CEO, Glynn Wilson, Ph.D....[+]
Tue, 25 Feb 2014 16:20:11 GMT
[at noodls] - SEATTLE, Feb. 25, 2014 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders. ... This is an abstract of the original ...